Molecular Medicine

, Volume 14, Issue 1–2, pp 20–27 | Cite as

Valproic Acid Sensitizes Chronic Lymphocytic Leukemia Cells to Apoptosis and Restores the Balance Between Pro- and Antiapoptotic Proteins

  • Imke Bokelmann
  • Ulrich Mahlknecht
Research Article


Chronic lymphocytic leukemia (CLL) is one of the most common leukemias in adults in the developed world. Despite significant advances in the treatment of cancer, CLL remains incurable. The main feature of the disease is the generation of circulating B-cells with prolonged survival caused by aberrant apoptosis. In this study, we observe that valproic acid (VPA), a well-established histone deacetylase (HDAC) inhibitor, mediates apoptosis in CLL cells ex vivo through caspase activation via both the extrinsic and the intrinsic apoptosis pathways, as indicated by the activation of the caspase proteins 8 and 9, and cleavage of the proapoptotic protein BID. The Bcl-2/Bax ratio was decreased as a consequence of decreased bcl-2 mRNA levels in response to treatment with VPA. With the results presented in this study, we have identified the HDAC inhibitor VPA as restoring the apoptotic pathways in CLL cells and thus their ability to undergo apoptosis.



This work was supported by grants from the Deutsche José Carreras Leukämie-Stiftung e.V. (DJCLS R 05/11), the Deutsche Forschungsgemeinschaft (MA 2057/2-4), and the German Cancer Research Center (DKFZ) intramural funding program. We thank Manfred Hensel for patient samples and Volker Eckstein for help with flow cytometry. This work has in part been carried out at the University of Heidelberg Medical Center and the German Cancer Research Center (DKFZ).


  1. 1.
    Chanan-Khan A, Porter CW. (2006) Immunomodulating drugs for chronic lymphocytic leukemia. Lancet Oncol. 7:480–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Bratton SB, MacFarlane M, Cain K, Cohen GM. (2000) Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp. Cell Res. 256:27–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Reed JC. (2000) Mechanisms of apoptosis. Am. J. Pathol. 157:1415–30.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bodmer JL, Holler N, Reynard S, et al. (2000) TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2:241–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12:611–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Chang HY, Yang X. (2000) Proteases for cell suicide: functions and regulation of caspases. Microbiol. Mol. Biol. Rev. 64:821–46.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Schmitz I, Walczak H, Krammer PH, Peter ME. (1999) Differences between CD95 type I and II cells detected with the CD95 ligand. Cell Death Differ. 6:821–2.CrossRefPubMedGoogle Scholar
  8. 8.
    Barnhart BC, Alappat EC, Peter ME. (2003) The CD95 type I/type II model. Semin. Immunol. 15:185–93.CrossRefPubMedGoogle Scholar
  9. 9.
    Jewell AP. (2002) Role of apoptosis in the pathogenesis of B-cell chronic lymphocytic leukemia. Br. J. Biomed. Sci. 59:235–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Pepper C, Hoy T, Bentley DP. (1997) Bcl-2/Bax ratios in chronic lymphocytic leukemia and their correlation with in vitro apoptosis and clinical resistance. Br. J. Cancer 76:935–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276:36734–41.CrossRefPubMedGoogle Scholar
  12. 12.
    Mahlknecht U, Hoelzer D. (2000) Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 6:623–644.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Johnstone RW, Licht JD. (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4:13–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Nebbioso A, Clarke N, Voltz E, et al. (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11:77–84.CrossRefPubMedGoogle Scholar
  15. 15.
    Insinga A, Monestiroli S, Ronzoni S, et al. (2005) Inhibitors of histone deacetylases induce tumorselective apoptosis through activation of the death receptor pathway. Nat. Med. 11:71–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1:194–202.CrossRefPubMedGoogle Scholar
  17. 17.
    Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 11(Suppl 2):S193–206.CrossRefPubMedGoogle Scholar
  18. 18.
    MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. (2005) TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 65:11265–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Muzio M, Salvesen GS, Dixit VM. (1997) FLICE induced apoptosis in a cell-free system: cleavage of caspase zymogens. J. Biol. Chem. 272:2952–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Stennicke HR, Jurgensmeier JM, Shin H, et al. (1998) Pro-caspase-3 is a major physiologic target of caspase-8. J. Biol. Chem. 273:27084–90.CrossRefPubMedGoogle Scholar
  21. 21.
    Slee EA, Harte MT, Kluck RM, et al. (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell. Biol. 144:281–92.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Aron JL, Parthun MR, Marcucci G, et al. (2003) Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and downregulation of c-FLIP protein. Blood 102:652–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Lucas DM, Davis ME, Parthun MR, et al. (2004) The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18:1207–14.CrossRefPubMedGoogle Scholar
  24. 24.
    Sartorius UA, Krammer PH. (2002) Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int. J. Cancer 97:584–92.CrossRefPubMedGoogle Scholar
  25. 25.
    Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. (1996) Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10:456–9.PubMedGoogle Scholar
  26. 26.
    Schmitz I, Kirchhoff S, Krammer PH. (2000) Regulation of death receptor-mediated apoptosis pathways. Int. J. Biochem. Cell Biol. 32:1123–36.CrossRefPubMedGoogle Scholar
  27. 27.
    Igney FH, Krammer PH. (2002) Death and anti-death: tumor resistance to apoptosis. Nat. Rev. Cancer 2:277–88.CrossRefPubMedGoogle Scholar

Copyright information

© Feinstein Institute for Medical Research 2008

Authors and Affiliations

  1. 1.Department of Hematology/Oncology, José Carreras Center for Immunotherapy and Gene TherapySaarland University Medical CenterHomburg/SaarGermany
  2. 2.Department of Hematology/OncologyUniversity of Heidelberg Medical CenterHeidelbergGermany

Personalised recommendations